New therapeutic approaches for cystic fibrosis lung disease.
Davies
Jane C
JC
Royal Brompton Hospital, Sydney Street, London SW3 6NT, UK. j.c.davies@ic.ac.uk
D000256:Adenoviridae; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001422:Bacterial Adhesion / Q000187:drug effects; D001428:Bacterial Vaccines; D018441:Biofilms / Q000187:drug effects; D003550:Cystic Fibrosis / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D017136:Ion Transport; D009154:Mutation / Q000235:genetics; D011480:Protease Inhibitors / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D001428:Bacterial Vaccines; C505032:CFTR protein, human; D011480:Protease Inhibitors; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D006493:Heparin